51 – 60 of 202
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission
- Contribution to journal › Article
-
Mark
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017
- Contribution to journal › Letter
-
Mark
The EHA Research Roadmap: Malignant Lymphoid Diseases
- Contribution to journal › Article
-
Mark
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
- Contribution to journal › Article
-
Mark
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
- Contribution to journal › Letter
-
Mark
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
- Contribution to journal › Article
-
Mark
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Tackling Mantle Cell Lymphoma in Europe
- Contribution to journal › Article
- 2021
-
Mark
Association between anthropometry and lifestyle factors and risk of B-cell lymphoma : An exposome-wide analysis
- Contribution to journal › Article
